AllSci News
ADA: Novo Nordisk posts more data for zenagamtide in Phase II for T2D
Novo Nordisk reported positive Phase II results for zenagamtide (also known as amycretin) in type 2 diabetes at the ADA 2026 Scientific Sessions, with the...
Oricell's GPC3 CAR-T advances to Phase II trial in hepatocellular carcinoma
Shanghai-based Oricell Therapeutics Holdings Limited announced that its GPC3 CAR-T therapy, Ori-C101, has received clearance from China's National Medical...
Sanofi and Kymera's second-generation IRAK4 degrader enters Phase I for hidradenitis suppurativa
Sanofi has initiated a first-in-human study of SAR447971 (also known as KT-485), an oral small-molecule IRAK4 targeted protein degrader discovered by...
Tango and Revolution Med's PRMT+RAS(ON) regimen achieves 92% response rate in pancreatic cancer
Early-stage combination data from Boston-based Tango Therapeutics (Nasdaq: TNGX) reported a 92% objective response rate for vopimetostat, its oral...
RemeGen beats Novartis to punch with China approval for telitacicept in Sjögren’s disease
China’s NMPA has approved telitacicept for the treatment of adult patients with Sjögren’s disease — marking the first regulatory approval of any…
Incyte to acquire Vega Therapeutics for USD 2.0b targeting mAb for VWD
Incyte (Nasdaq: INCY) has agreed to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC, for USD 1.25 billion upfront, with...
GSK partners with Engitix on liver fibrosis regression using human extracellular matrix platform, up to USD 59.4m upfront
GSK has entered a research collaboration and option agreement with UK-based Engitix Ltd. to identify and validate novel therapeutic targets for liver...
Sanofi expands Owkin partnership for purpose-built AI agents
Sanofi has signed a multi-year collaboration agreement with Owkin, the Franco-American agentic AI company, to co-develop bespoke AI agents deployed through...
Shilpa Medicare takes equity stake in Gate2Brain for preclinical brain cancer peptide conjugate
India-based Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Spain-based Gate2Brain, S.L. to advance G2B-002, a...
GNI Group acquires Ayumi Pharmaceutical from Blackstone for USD 280m
Japan-based GNI Group Co., Ltd. (TSE: 2160) has agreed to acquire 100% of the shares of Ayumi Pharmaceutical Holdings Co., Ltd. from shareholders led by...
Everest Medicines gains exclusive Greater China rights to Corxel's presbyopia eye drop
Everest Medicines (HKEX: 01952) has secured exclusive rights to develop and commercialize LNZ100, a once-daily aceclidine eye drop for presbyopia, across...
Karo expands license with Moberg Pharma to include China e-commerce
Karo Healthcare has extended its license agreement with Stockholm-based Moberg Pharma (Nasdaq Stockholm: MOB) to cover China, adding the world's most...
Roche commits USD 700m upfront to co-develop Nurix BTK degrader bexobrutideg across oncology and immunology
Roche commits USD 700 million upfront — one of the largest deals in the targeted protein degradation space — to co-develop and co-commercialize...
Sanofi’s subcutaneous Sarclisa cleared in EU for multiple myeloma via on-body injector
The European Commission has approved Sarclisa (isatuximab) subcutaneous as the first anticancer therapy in the EU to be administered via an on-body…
Boehringer posts detailed data from survodutide Phase III showing visceral and liver fat reduction
Boehringer Ingelheim reported detailed Phase III results for survodutide (BI 456906), a glucagon/GLP-1 receptor dual agonist licensed from Denmark-based...
The AllSci Brief
Systematic R&D and deal news. Daily.